Left Ventricular Hypertrophy
79
12
12
45
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.3%
5 terminated out of 79 trials
90.0%
+3.5% vs benchmark
30%
24 trials in Phase 3/4
11%
5 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (79)
AI-based Echocardiography for Detection of Cardiac Amyloidosis
SGLT2 Inhibition in Hemodialysis
Left Ventricular Hypertrophy in CKD Patients
ReNEW Clinic Cohort Study
Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Diffusion MRI in Heart Failure
Imaging Histone Deacetylase in the Heart
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
US Benchmarking Clinical Study
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy
Sodium Lowering Vascular Effects Trial
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography
Mechanism of Decompensation Evaluation - Aortic Stenosis
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Access Creation for Hemodialysis: Association With Structural Changes of the Heart